Health Care Equipment & Supplies

Medtronic plc is trading at roughly 14.4 times forward earnings at $86.38 per share after raising its fiscal 2027 organic revenue growth and diluted non-GAAP EPS outlook in September. The company now expects organic revenue growth of 7.25% to 7.75% and full-year diluted non-GAAP EPS of $5.94 to $6.00, following first-quarter non-GAAP diluted EPS of $1.45 that came in ahead of guidance. Fiscal 2027 first-quarter revenue rose 13.7% organically to $9.8 billion, though Medtronic estimated that an extra fiscal week in the quarter contributed approximately $570 million to organic growth, making the headline rate look stronger than underlying recurring growth. Cardiovascular led the quarter with organic revenue up 18.9%, including 88% growth in Cardiac Ablation Solutions and 29.1% growth in Electrophysiology Therapies, while Neuroscience rose 9.3%, Medical Surgical grew 10.2%, and Diabetes rose 14.9% organically. The company has also expanded through the acquisitions of Scientia Vascular and SPR Therapeutics and announced further investments in robotic-assisted surgery and leaflet modification technology. Medtronic shares have declined more than 7% over the past 12 months, compared with a 17% gain for the broader market.

Becton Dickinson agreed to invest $3 billion to bring manufacturing of essential medical products to the United States, part of a broader plan to invest $19 billion in the country over several years across capital, operations and supply-chain initiatives, President Donald Trump said Monday in a post on Truth Social. More than $1 billion of that $3 billion will go to Nebraska to ramp up production of numerous products, including needles made with American steel, and BD expects to increase domestic production of essential medical consumables by about 5 billion units annually, raising the share of such products supplied from within the U.S. to roughly 80%. Separately, Viatris entered a definitive agreement to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, in a deal expected to close by the end of 2026 that adds the patent-protected pain therapies EXPAREL and ZILRETTA; Pacira generated approximately $746 million in total revenue and about $177 million in adjusted EBITDA in the twelve months ended June 30, 2026. CSL and Alentis Therapeutics entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver and other diseases, with CSL making an initial payment of $355 million and Alentis eligible for up to $1.2 billion in commercial milestone payments, and the companies sharing global profits 55% to CSL and 45% to Alentis once the drug is commercialized. Novavax and Moderna traded flat in the premarket on Tuesday after the WHO said Russian officials had traced all contacts of a plague research lab employee who died of pneumonia of an unknown cause, though Novavax closed 20% higher and Moderna added 7% on Monday after Russia's Rospotrebnadzor reported the death of the 28-year-old worker at the Irkutsk Research Anti-Plague Institute of Siberia.

Abbott Laboratories reported a 13% year-on-year revenue increase in the second quarter of 2026, with like-for-like sales up 4.8%, and announced a quarterly dividend of $0.63 per share, an annualized payout of $2.52. The company has raised its dividend for 54 consecutive years, though its annualized payout ratio of about 82% of trailing earnings of $3.09 per share sits on the high side, while its free-cash-flow payout ratio is roughly 56% on about $9.9 billion in operating cash flow and $7.8 billion in free cash flow over the past 12 months. Abbott's acquisition of Exact Sciences has expanded its cancer diagnostics business, and it recently obtained a CE Mark for Libre Duo, a sensor tracking both glucose and ketone levels. In the first half of 2026, reported sales rose 10.5% while comparable sales rose 4.3%, and trailing-12-month revenue has reached around $46.6 billion. The stock trades at about 33.5 times trailing earnings and 17 times forward earnings, with a dividend yield of about 2.5%.

Abbott Laboratories introduced Ensure Max Protein 3-in-1 Muscle Support, a combined protein, creatine, and HMB powder that is NSF certified and targets muscle building, recovery, and preservation for everyday active consumers and athletes. The launch expands Abbott's nutrition portfolio beyond devices and diagnostics into a broader performance-focused supplement offering, edging the company into a space where firms like Nestlé Health Science and Danone are already active. The product lands in Abbott's Nutrition segment, which the company's narrative casts as rebuilding trust and profitability after legal issues while medical technology and diagnostics do the heavy lifting for future earnings. Relative to large-ticket catalysts such as Libre, electrophysiology tools and Cancer Diagnostics, Ensure Max Protein looks more like incremental support for Nutrition recovery than a central earnings driver, especially with analysts still flagging legal exposure and margin pressure in the segment.

A court in Amsterdam on Saturday denied demands by shareholders of Philips for an investigation into the company over its handling of a massive product recall involving its sleep apnea and ventilator machines in 2021. The Enterprise Chamber of the Amsterdam Court of Appeal ruled in favor of the company, dealing a setback to a large group of Philips shareholders, including the Dutch investors' association, VEB, and several institutional investors. The shareholders called for a court inquiry after the Dutch medtech launched a recall of roughly 3.5M breathing machines in 2021 due to concerns that a polyurethane foam used in the devices could deteriorate and become toxic. The investors argued that the company failed to identify and address the issues promptly due to weaknesses in its internal systems, and alleged that the Philips board of directors was aware of the problems at the company's Respironics U.S. unit, which made the devices, well before the disclosures were made regarding the issue. The chamber said there is no reason to assume that Philips ought to have intervened at Respironics earlier, or that the Supervisory Board exercised insufficient oversight, and added that there is no sufficient basis to determine that Philips' disclosures to the investors were late, incorrect, or misleading. The chamber didn't rule on whether there were errors at Respironics or regarding the extent of liability for damages faced by investors.

A Dutch court on Saturday dismissed shareholders' demands for an investigation into Koninklijke Philips NV's handling of its 2021 sleep apnea device recall, siding with the health technology company over allegations that management failed to act promptly on safety concerns and misled investors. The Enterprise Chamber of the Amsterdam Court of Appeal said it found no sufficient grounds to question Philips' policies or management practices that would justify an inquiry, following a review of extensive case files and internal documents. The shareholders, including Dutch investors' association VEB and a large group of retail and institutional investors, had argued that Philips' internal controls failed to identify and address problems with the recalled devices promptly, that its board knew or should have known about the risks before they became public, and that its disclosures breached legal obligations. The court found that sufficient reliable research data pointing to potential health risks from the PE-PUR sound-abatement foam became available only in the first months of 2021, and found no basis to conclude Philips should have intervened earlier at its U.S. subsidiary Respironics. The ruling does not determine whether errors were made at Respironics or decide whether investors are entitled to compensation, addressing only whether there were grounds to order an investigation. Philips recalled around 15 million sleep apnea and respiratory devices globally in 2021, a recall that caused its shares to lose about two-thirds of their value; the company agreed in 2024 to pay $1.1 billion to settle all personal injury claims filed in the United States, and investigations continue in multiple countries, including France, where prosecutors are examining allegations of aggravated fraud and failure to report safety risks.

NovoCure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax, a portable Tumor Treating Fields device, for use with gemcitabine and nab-paclitaxel in adults with unresectable locally advanced pancreatic cancer. The decision, announced in October 2026, was based on the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in median overall survival. The approval extends TTFields therapy into a new, hard-to-treat solid tumor indication in Japan, supported by largely manageable skin-related side effects that may encourage clinician adoption. It builds directly on the February 2026 FDA approval of Optune Pax in locally advanced pancreatic cancer alongside gemcitabine and nab-paclitaxel, reinforcing the view that regulators in more than one major market consider the PANOVA-3 data clinically meaningful. NovoCure's narrative projects $915.6 million in revenue and $119.8 million in earnings by 2029, while some optimistic analysts assume revenue could reach about US$1.1 billion and earnings US$70 million by 2029.

Nipro's U.S. unit has completed enrollment in the GREAT trial for the Golazo Peripheral Atherectomy System, a clinical milestone the company says could matter for long-term sentiment. The Japanese medical equipment maker's shares trade at ¥1,319, with a one-year total shareholder return down 9.73% after a weaker 90-day share price return of 14.71%, though investors who held through the last three years still see a 30.60% total shareholder return. Nipro trades on a price-to-earnings ratio of 15.6x, below the JP Medical Equipment industry average of 16x, the peer average of 19.4x, and an estimated fair P/E of 18.8x, while recent earnings growth of 144.4% over the past year and higher net profit margins of 2.1% compared to 0.9% last year give context for the mid-teens multiple. The SWS discounted cash flow model, however, sends a different signal, with the share price of ¥1,319 against an estimated future cash flow value of ¥938.68 suggesting the stock screens as overvalued.

Toho Holdings is in advanced talks to acquire PHC Holdings in a potential Japan healthcare sector transaction valued at more than JPY 200 billion. The move would push the ¥240.1 billion pharmaceutical wholesaler further into medical devices, diagnostic reagents and healthcare technology, turning a pure distributor into a broader healthcare platform. The talks reflect a wider trend of privatizations and consolidation in Japan's healthcare industry. The key question now is whether Toho Holdings moves from due diligence to a formal tender offer, and on what terms, with investors likely to focus on the premium to PHC's last trading price, the proposed financing mix, and any concrete targets for returns or cash generation. Questions already surround dividend coverage by free cash flow and past one-off items in results, so higher funding needs and integration risk could weigh on the stock if the deal proceeds.

Glaukos Corp. said its iDose TR travoprost intracameral implant met the primary goal of a phase 4 trial in patients with open-angle glaucoma or ocular hypertension. At three months, participants who underwent cataract surgery and received iDose TR saw a mean diurnal intraocular pressure reduction of 11.1 mmHg from baseline, compared with 7.4 mmHg for those who had cataract surgery alone. The iDose TR arm was also superior to cataract surgery alone in secondary responder analyses. No treatment-related adverse events of corneal endothelial cell loss, cystoid macular edema, or serious corneal adverse events were reported. iDose TR is designed to provide a continuous supply of travoprost inside the eye for up to three years.

Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop and commercialize RO-104, an investigational tri-specific biologic for multiple retinal diseases, while gaining exclusive rights to the RevMod platform to discover and develop up to four additional retinal biologic candidates. RO-104 is a first-in-class tri-specific biologic with a high-concentration formulation that inhibits VEGF-A, VEGF-C and Ang-2, three clinically validated pathways involved in retinal vascular diseases, and is being developed for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. In established preclinical animal models, the candidate demonstrated superior efficacy compared with approved anti-VEGF therapies, and the license covers the RevMod platform across geographic atrophy, DME, DR, RVO and nAMD. Chairman and CEO Thomas Burns said the addition of RO-104 and exclusive access to the RevMod platform marks a strategic step in expanding the company's retinal franchise and complements its existing retinal R&D initiatives. Financial terms of the agreement were not disclosed. Following the announcement, GKOS stock lost 6.3% at yesterday's close, though it has gained 42.8% year to date, and the company currently has a market capitalization of $10.16 billion.

Becton Dickinson is positioned to potentially extend its earnings-beat streak when it reports next on November 5, 2026, according to Zacks Investment Research. The medical device manufacturer has beaten estimates in each of its last two quarters, with an average surprise of 3.78%. In its most recent report, Becton Dickinson posted earnings of $3.23 per share against the Zacks Consensus Estimate of $3.14, a surprise of 2.87%, following a prior-quarter result of $2.9 per share versus an expected $2.77, a surprise of 4.69%. The company currently carries an Earnings ESP of +0.21% alongside a Zacks Rank #3 (Hold), a combination that Zacks research shows produces a positive surprise nearly 70% of the time.

GE HealthCare announced a definitive agreement on October 5 to acquire Sofie Biosciences for $945 million in cash, with closing expected in the first half of 2027. The deal builds on an exclusive licensing agreement struck in October 2023 covering development and commercialization of Fluorine-18 FAPI-74 outside the United States and global rights to Gallium-68 FAPI-46, and it would add U.S. rights to F-18 FAPI-74 while expanding GE HealthCare's domestic radiopharmaceutical manufacturing network. The company also recently received CE Mark approval for its Photonova Spectra photon-counting CT scanner, its third clearance across key geographies in five months. In the second quarter of fiscal 2026, adjusted EBIT margin fell 40 basis points year over year to 14.2%, though diluted EPS rose 16.5%, a figure that included a one-time $129 million tariff refund under the International Emergency Economic Powers Act. After $2.3 billion of strategic acquisitions in the first half, GE HealthCare reported $10.1 billion in total debt and $2.1 billion in cash and equivalents at quarter-end.

Tandem Diabetes Care is broadening its product roadmap with new integrations, wider device compatibility and next-generation closed-loop technology while pushing international expansion. In second-quarter 2026, international sales rose 7% year over year to $75.3 million and pump shipments increased 19% to about 11,000, with direct-channel sales reaching about 13% of international revenues compared with 4% a year earlier. The company submitted a 510(k) for Mobi tubeless in the second quarter of 2026 and still targets a scaled launch in 2026 subject to FDA clearance, while Dexcom G7 15-day compatibility is now available for Mobi and t:slim X2 in the United States and t:slim X2 supports Abbott FreeStyle Libre 3 Plus in seven countries outside the United States. Tandem also received FDA approval of an IDE for its AIDANET fully closed-loop program and plans to begin a pivotal study later in 2026. Tandem ended the quarter with $456 million of cash, cash equivalents and short-term investments and no short-term debt, though a key infusion set supplier constrained supply sales and inventory, and the 10-Q states inventory constraints are expected to persist through 2026. The Zacks Consensus Estimate for Tandem's 2026 loss per share stands at 66 cents, indicating a year-over-year improvement of 74.4%, while 2026 revenues are pegged at $1.07 billion, a 5.7% increase from the year-ago reported number.

Profound Medical Corp. and Telix Pharmaceuticals Limited have entered into a co-education agreement to advance PSMA-informed prostate care, the companies announced on October 9, 2026. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, along with educational content, clinical case studies and best-practice materials. Profound said the collaboration increases its access to urologists across the U.S. and internationally through a strong strategic partner, and that it is also developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. Profound CEO and Chairman Arun Menawat said the agreement supports broader market development and could strengthen the clinical and economic value proposition of TULSA-PRO centers, while Telix Precision Medicine CEO Kevin Richardson said the collaboration aims to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy.

Glaukos Corporation announced positive topline results from its Phase 4 GLK-101-04 clinical trial showing that iDose TR administered in combination with cataract surgery achieved statistically significant and clinically meaningful intraocular pressure reduction compared to cataract surgery alone. At month 3, eyes receiving cataract surgery plus iDose TR achieved a mean diurnal IOP reduction of 11.1 mmHg from baseline, versus 7.4 mmHg for cataract surgery alone, an incremental treatment effect of 3.6 mmHg with a p-value of less than 0.0001. The study randomized 149 eyes, with 74 assigned to the combination arm and 75 to cataract surgery alone, and met its primary efficacy endpoint as well as all pre-specified secondary responder analyses. iDose TR also showed a favorable safety profile through 3 months, with no treatment-related adverse events of corneal endothelial cell loss or cystoid macular edema and no serious corneal adverse events. Glaukos chairman and chief executive officer Thomas Burns said the data reinforce the versatility of iDose TR, a first-of-its-kind long-duration intracameral procedural pharmaceutical therapy designed to deliver 24/7 therapeutic levels of travoprost inside the eye for up to three years, whether administered as a standalone procedure or in conjunction with cataract surgery.

Becton Dickinson's Revello Vascular Covered Stent hit the primary endpoint in iliac artery disease in nine-month results from the AGILITY trial. The clinical data arrived during a busy October for the company that also brought a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the portfolio. The shares have gained 20.28% over the past 90 days even as the year-to-date share price return stands at a 6.25% decline, and the 1-year total shareholder return of 26.07% points to building momentum. The most followed valuation narrative puts Becton Dickinson's fair value at $195.67 against a last close of $182.75, implying the rally has not fully closed the gap those followers see. That narrative rests on a focused medtech portfolio in which more than 90% of revenue comes from businesses growing in the mid to high single digits, with platforms such as biologic drug delivery, Advanced Patient Monitoring, PureWick and advanced tissue regeneration growing at double digits, plus about $2.3b of share repurchases year to date in fiscal 2026, $3.1b returned to shareholders in total and $2.1b of debt retired while keeping net leverage around 2.9x. Becton Dickinson still faces real pressure if China weakness persists and if recalls or FDA actions around infection prevention products expand or take longer to resolve.

Danaher announced in early October 2026 that it had launched its first AI-powered autonomous lab at Abcam, combining artificial intelligence, robotics and connected workflows to accelerate the design, building and testing of custom antibodies and other molecular tools. The lab's closed-loop system feeds every experimental result back into its AI models, a setup intended to lift both the speed and scale of reagent discovery while maintaining rigorous validation. The launch reinforces Danaher's Life Sciences automation and AI catalyst but does not materially change near-term sensitivities around bioprocessing demand or the risk that softer respiratory testing and China pricing could leave overall growth below what the market currently embeds. The announcement comes alongside the appointment of Julie Sawyer Montgomery as CEO from 1 October 2026, with execution on connected, automated workflows expected to depend heavily on leadership continuity and capital allocation discipline. Danaher's narrative projects $31.7 billion revenue and $6.1 billion earnings by 2029, requiring 8.1% yearly revenue growth and about a $2.1 billion earnings increase from $4.0 billion today, while three Simply Wall St Community fair value estimates cluster in a tight US$225.66 to US$239.86 range.

ZJ Bio-Tech announced on October 9 that as of September 30, 2026, the company had repurchased a cumulative 5.51 million shares, accounting for 2.90% of total share capital, with total repurchase funds of 105 million yuan and a repurchase price range of 14.71 yuan to 23.49 yuan per share. In the first half of 2026, ZJ Bio-Tech achieved revenue of 53.39 million yuan and a net loss attributable to the parent company of 40.59 million yuan.

Sino Medical announced that its SCHONKYTONK coronary balloon dilatation catheter has received approval from Colombia's INVIMA and obtained a medical device registration certificate. The product is indicated for balloon catheter dilatation of stenotic segments of coronary arteries or stenosis at bypass graft sites to improve myocardial perfusion. The company stated that this approval is an important part of its overseas business expansion and will help drive overseas sales of the product.

MicuRx Pharmaceuticals has signed an exclusive license agreement and a platform technology collaboration agreement with Switzerland's ClearideBio for the MRX-23 project. The nominal cap on milestone payments for the development, registration, and sales of MRX-23 totals 223 million US dollars, while the cap for all platform collaboration projects, if all options are exercised and all milestones are achieved, totals 750 million US dollars. Under the agreement, an upfront payment of 1 million US dollars is payable as agreed after the agreement takes effect and is non-refundable, and near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. Biwin Storage Technology announced that as of September 30, 2026, it had cumulatively repurchased 1,044,700 shares, accounting for 0.22 percent of total share capital, with a total payment of 222 million yuan. The repurchase plan is expected to involve a total amount of 200 million to 250 million yuan. Sino Medical Sciences Technology's coronary balloon dilatation catheter has received approval from Colombia's INVIMA and obtained a medical device registration certificate. Jiangsu Jindike Biotechnology's trivalent influenza vaccine has obtained a drug registration certificate, but the company expects full-year revenue may fall below 100 million yuan and it will not be able to turn a profit. If it triggers the financial delisting risk warning conditions, the Shanghai Stock Exchange will impose a delisting risk warning on the company's shares.

SS Innovations International reported 195 robotic telesurgeries performed with its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. Founder and CEO Dr. Sudhir Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets.

Medtronic plc reported 13.7% organic and reported topline growth in its first quarter, with revenue reaching $9.756 billion and adjusted earnings of $1.45 per share. Double-digit year-over-year growth was seen across all major segments, with Cardiovascular up 19.5%, Diabetes up 16.9%, Neuroscience up 10.3% and Medical Surgical up 10%, though an extra fiscal week added approximately $570 million to quarterly revenue. CFO Thierry Piéton said the Cardiac Ablation Solutions segment is annualizing at more than $2 billion in revenue, and the unit surpassed $2 billion in trailing 12-month revenue in Q1 FY27, ahead of management's target. The company made a $700 million strategic investment in Cornerstone Robotics that includes rights to distribute the Sentire Surgical System in select markets outside the US, complementing its existing Hugo robotic-assisted surgery system. Medtronic carries a market capitalization of almost $109.3 billion, with $37.54 billion in revenue over the prior twelve months, an operating margin of 19.33% and a net margin of 13.93%; the stock trades at a trailing price-to-earnings multiple of 22x and a forward P/E of 14.93x. Hedge fund holdings rose to 67 in the second quarter of 2026 from 60 in the prior quarter, while BlackRock is the largest institutional investor with 114.02 million shares, or 8.91% of outstanding shares.

Glaukos Corporation reported positive three-year extension trial results for its non-invasive keratoconus treatment Epioxa while simultaneously securing an exclusive licensing deal to broaden its retinal disease pipeline. In the GLK-202-03 extension study, 38 study eyes across 35 subjects were followed for up to three years after a single Epioxa treatment with no further medical interventions, and 92% of participant eyes completed the final three-year assessment visit. Treated eyes maintained a 1.9 diopter improvement in maximum corneal curvature from baseline, while 29% of eyes gained two or more lines of best-corrected visual acuity and 20% gained three or more lines, with zero serious adverse events, treatment-related adverse events, or therapy-related discontinuations. Separately, Glaukos announced an exclusive licensing agreement with RevOpsis Therapeutics Inc. to develop and commercialize RO-104, a first-in-class tri-specific biologic targeting neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, which blocks VEGF-A and VEGF-C while inhibiting Ang-2. The deal grants Glaukos exclusive rights to use the RevMod platform to develop up to four additional retinal biologics, with financial terms not disclosed. Glaukos shares were down 10.76% at $153.65 at the time of publication on Thursday.

Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant, initially rolling out across 12 European markets including Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland and the United Kingdom, with additional countries expected to follow. The launch follows the implant's U.S. introduction in 2024 and is part of the company's strategy to expand access to differentiated Sports Medicine technologies. The rollout is backed by a multicenter, randomized controlled trial published in the American Journal of Sports Medicine showing patients treated with CARTIHEAL AGILI-C achieved higher overall Knee injury and Osteoarthritis Outcome Scores than those receiving surgical standard of care through 60 months, with outcomes not statistically different between patients with and without osteoarthritis. The expansion comes as Smith+Nephew's Sports Medicine & ENT revenues rose 10% year over year on a reported basis in the second quarter of 2026, while Sports Medicine Joint Repair revenue rose 11.8%, with the company highlighting strong growth from CARTIHEAL AGILI-C. Smith+Nephew currently has a market capitalization of $11.28 billion, and its shares have lost 18% year to date compared with the industry's 23.4% decline.

Glaukos reported positive topline results from a long-term Phase 3 extension study of Epioxa, showing three-year durable efficacy, clinically meaningful visual gains, and no serious safety issues in keratoconus patients after a single epi-on corneal cross-linking treatment. The company also raised its 2026 net sales guidance to US$680 million to US$700 million, helped by contributions from iDose TR and Epioxa. Glaukos' narrative projects $1.2 billion revenue and $132.4 million earnings by 2029, while the most cautious analysts assumed about US$1.0 billion of revenue and only US$75.5 million of earnings by 2029. The new long-term Epioxa results support the idea that corneal therapies can be a meaningful second pillar alongside glaucoma, though they sit within the same execution and reimbursement risks that already define the main catalysts for the stock.

Glaukos Corporation shares fell more than 13% on Thursday after an insider sale by the company's chief development officer, Tomas Navratil, overshadowed positive late-stage trial data for its Epioxa eye therapy. According to a regulatory filing on Tuesday, Navratil sold more than 1,500 shares in three transactions at an average range of $163.93 to $165.60, consistent with a 10b5-1 trading plan adopted on June 12. The transactions, valued at $251.1K in total, took place on Monday and lowered Navratil's stake in the company by nearly 2% to 69,291 shares. The disclosure overshadowed a Wednesday announcement that three-year results from a Phase 3 extension study showed a single Epioxa treatment, approved in the U.S. to treat keratoconus, can deliver durable efficacy with a favorable long-term safety profile. Separately on Thursday, Glaukos announced an exclusive license agreement with privately held RevOpsis Therapeutics to develop and commercialize RO-104, an experimental therapy for multiple retinal diseases, and said it also receives exclusive rights to RevOpsis' proprietary RevMod platform to develop up to four more retinal biologics; financial terms were not disclosed.

Danaher announced the launch of its first AI powered autonomous laboratory aimed at accelerating life sciences research. The facility integrates artificial intelligence, robotics, and Danaher proprietary technologies to automate complex experimental workflows, with company materials highlighting use cases such as faster development of custom antibodies and other research tools for biomedical customers. The new autonomous facility targets faster creation of antibodies and other affinity reagents, and the company frames the potential to move from idea to tested reagent 8x faster while expanding output from tens to hundreds of reagents per year. The launch feeds into Danaher's existing narrative around AI linked life sciences demand and higher value automation, drawing together robotics and smart instruments across its operating companies. The clearest near term signpost is how management describes uptake of autonomous workflows and reagent output at Abcam as the lab scales toward early 2027, along with metrics on reagent throughput, customer adoption in biopharma and academia, and cross selling into Beckman Life Sciences, bioprocessing, or diagnostics platforms.

Haemonetics Corporation shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc. CSL announced on October 8, 2026, that it expects to complete the rollout of Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of calendar year 2027, according to an 8-K filing, and told Haemonetics it currently anticipates the transition will occur at all of its U.S. plasma collection centers. The companies initially entered into the non-exclusive supply agreement on August 18, 2026, under which CSL may utilize Haemonetics' devices and purchase related disposables in the United States. Haemonetics said the scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement and that implementation details are still to be determined, and it is not updating its previously issued fiscal 2027 guidance at this time. The company expects to provide an update regarding the anticipated impact of the supply agreement on its fiscal 2027 financial results during its second fiscal quarter earnings call in November 2026.

Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance new prostate cancer-specific genomic instability score technology, known as PrGIS, with AstraZeneca. PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients, and Myriad's proprietary MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad's PrGIS technology, drawing on a cloud-based platform with more than 1,000 connected institutions in over 75 countries. Myriad also plans to present PrGIS research co-authored with AstraZeneca at the European Society for Medical Oncology Congress 2026, with full data available after the ESMO embargo period.

Nexalin Technology announced Thursday that it has received written confirmation from Nasdaq that the company has regained compliance with the minimum bid price requirement. Nasdaq confirmed that the closing bid price of the company's common stock stayed above the $1.00 per share minimum for 21 consecutive trading days, from August 31 through September 29, 2026, following the company's previously announced reverse stock split. Under the terms of the Panel's decision, the company was required to demonstrate compliance with the bid price requirement, which it has now satisfied, and must still demonstrate compliance with the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rules on or before January 4, 2027. The company's continued listing on Nasdaq remains subject to the terms of the panel's decision, including that stockholders' equity requirement. Shares of NXL slipped nearly 1.4% pre-market.

Nexalin Technology said it has regained compliance with Nasdaq's minimum bid price requirement after the closing bid price of its common stock stayed above $1.00 per share for 21 consecutive trading days, from August 31 through September 29, 2026, following its previously announced reverse stock split. The confirmation, dated September 30, 2026, follows a September 25, 2026 decision by the Nasdaq Hearings Panel granting the company's request for continued listing. Under the Panel's decision, Nexalin must still demonstrate compliance with the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) on or before January 4, 2027. Chief Executive Officer Mark White said the company's primary focus remains on business momentum, citing a recently announced distribution agreement covering Brazil and six additional South American markets and the advancement of its U.S. clinical programs, including the pivotal HALO Clarity clinical trial in insomnia. Nexalin said its continued listing remains subject to the Panel's terms, including prompt notification of any significant events during the exception period, and that there can be no assurance it will meet the stockholders' equity requirement in time.

Goldman Sachs upgraded Sonova Holding to buy from neutral and raised its price target to CHF315 from CHF230, sending the hearing-aid maker's shares to a 16-month high. The stock rose around 0.5% to its highest level since June 11, 2025, outperforming a broader Swiss market that saw the SMI fall about 0.8% on Thursday. Goldman Sachs said Sonova is well positioned to outperform the overall hearing-aid market, citing product innovation, opportunities to gain market share in Asia and improving industry fundamentals. The broker expects the company to deliver around 9% constant-currency revenue growth in the first half of fiscal 2027, well above Visible Alpha consensus of 6.2%, which it sees as a potential catalyst for the shares. Goldman now expects Sonova to reach the upper end of its FY27 guidance, forecasting 7.8% constant-currency revenue growth versus 6.6% consensus, while adjusted EBIT growth including FX is seen at 12.6% versus 6.5% consensus, and it raised FY27-29 revenue estimates by 4%-7% and adjusted EBIT and EPS estimates by 7%-10%. The next major catalyst is Sonova's November 12 first-half FY27 results, where Goldman expects the company's stronger-than-consensus growth to become more visible.